当前位置: 首页 >> 检索结果
共有 3618 条符合本次的查询结果, 用时 3.6493452 秒

2941. Resuscitation from severe acute hypercapnia. Determinants of tolerance and survival.

作者: R T Potkin.;E R Swenson.
来源: Chest. 1992年102卷6期1742-5页
A 46-year-old man underwent cosmetic facial surgery under general anesthesia. He was ventilated by mask with an oxygen-enriched gas mixture for 4 to 6 h and monitored by pulse oximetry. Despite adequate arterial saturation (SaO2 > 90 percent) throughout the procedure, he remained in a deep coma after termination of anesthesia. Initial arterial blood gas analysis revealed a pH of 6.60 and a PaCO2 of 375 mm Hg. The patient was intubated and placed on mechanical ventilation. As his respiratory acidosis resolved, he regained consciousness quickly and recovered without any neurologic deficits. This case of record extreme hypercapnia and review of the literature demonstrates that survival is possible in acute severe respiratory acidosis as long as tissue anoxia and ischemia are prevented. We discuss the tissue effects of acute hypercapnia and newer aspects of the nature of intracellular pH regulation in critical tissues that afford considerable tolerance to acidosis. The dependence of these mechanisms upon active ion transport underscores the importance of adequate tissue oxygenation and perfusion.

2942. Prophylaxis of thromboembolism in spinal cord-injured patients.

作者: D Green.
来源: Chest. 1992年102卷6 Suppl期649S-651S页

2943. Patient selection for clinical investigation of ventilator-associated pneumonia. Criteria for evaluating diagnostic techniques.

作者: S K Pingleton.;J Y Fagon.;K V Leeper.
来源: Chest. 1992年102卷5 Suppl 1期553S-556S页

2944. International Consensus Conference: clinical investigation of ventilator-associated pneumonia. Introduction.

作者: G U Meduri.;W G Johanson.
来源: Chest. 1992年102卷5 Suppl 1期551S-552S页

2945. Pathogenesis and management of acute heart failure and cardiogenic shock: role of inotropic therapy.

作者: A I McGhie.;R A Golstein.
来源: Chest. 1992年102卷5 Suppl 2期626S-632S页
Patients with acute heart failure or cardiogenic shock following myocardial infarction have a high mortality. The first priority is to salvage any remaining viable myocardium, either by thrombolytic agents or, if necessary, by coronary angioplasty. A mechanical cause for the heart failure or shock needs to be excluded. Thereafter, the optimal therapeutic regimen needs to be chosen on the basis of each patient's hemodynamic profile. Patients can be broadly classified into three groups: (1) patients with a high left ventricular filling pressure (> 18 mm Hg) and a cardiac index < 2.2 L/min/m2 but systolic arterial pressure > 100 mm Hg; (2) patients with a systolic arterial pressure < 90 mm Hg, left ventricular filling pressure > 18 mm Hg, and cardiac index < 2.2 L/min/m2; and (3) patients with an elevated right ventricular filling pressure (> 10 mm Hg) and cardiac index < 2.2 L/min/m2 and a systolic arterial pressure < 100 mm Hg. Patients in the first subset usually require the use of vasodilator therapy and/or dobutamine. The choice of inotropic agent in patients in the second hemodynamic subset depends on the degree of systemic hypotension; dopamine is usually preferred initially because it increases arterial pressure in addition to improving cardiac output. Once the systemic blood pressure has been stabilized, dobutamine can be substituted for superior augmentation of cardiac output and its additional beneficial effects on the left ventricular filling pressure. Norepinephrine may be indicated in cases of severe systemic hypotension. Patients in hemodynamic subset 3, ie, right ventricular infarction, are treated with volume expansion and dobutamine. Use of nonpharmacologic means of circulatory support, eg, intra-aortic balloon pump or left ventricular assist device may also be required in any of these subsets.

2946. Nonpharmacologic management of cardiac arrest and cardiogenic shock.

作者: I F Goldenberg.
来源: Chest. 1992年102卷5 Suppl 2期596S-616S页

2947. Pathogenesis of low output in right ventricular myocardial infarction.

作者: K Chatterjee.
来源: Chest. 1992年102卷5 Suppl 2期590S-595S页

2948. Methodology for clinical investigation of ventilator-associated pneumonia. Epidemiology and therapeutic intervention.

作者: R G Wunderink.;C G Mayhall.;C Gibert.
来源: Chest. 1992年102卷5 Suppl 1期580S-588S页

2949. The standardization of criteria for processing and interpreting laboratory specimens in patients with suspected ventilator-associated pneumonia.

作者: V S Baselski.;M el-Torky.;J J Coalson.;J P Griffin.
来源: Chest. 1992年102卷5 Suppl 1期571S-579S页

2950. Guidelines for reading and interpreting chest radiographs in patients receiving mechanical ventilation.

作者: H T Winer-Muram.;S A Rubin.;M Miniati.;J V Ellis.
来源: Chest. 1992年102卷5 Suppl 1期565S-570S页

2951. The standardization of bronchoscopic techniques for ventilator-associated pneumonia.

作者: G U Meduri.;J Chastre.
来源: Chest. 1992年102卷5 Suppl 1期557S-564S页

2952. Early congestive heart failure due to origin of the right coronary artery from the pulmonary artery.

作者: U Vairo.;B Marino.;G De Simone.;C Marcelletti.
来源: Chest. 1992年102卷5期1610-2页
We describe a two-month-old infant with early congestive heart failure due to anomalous origin of the right coronary artery from the pulmonary artery. The diagnosis was made by two-dimensional and color flow Doppler echocardiography, confirmed by angiocardiography, and the case was successfully corrected at surgery. As opposed to the more frequent anomalous origin of the left coronary artery from the pulmonary trunk, this anomaly generally does not cause any typical clinical finding, often becoming an autoptic or surgical surprise after infancy or in adult age.

2953. Transmission of Legionella by respiratory equipment and aerosol generating devices.

作者: A H Woo.;A Goetz.;V L Yu.
来源: Chest. 1992年102卷5期1586-90页

2954. Antithrombotic therapy for cerebrovascular disorders.

作者: D G Sherman.;M L Dyken.;M Fisher.;M Gent.;M Harrison.;R G Hart.
来源: Chest. 1992年102卷4 Suppl期529S-537S页

2955. Antithrombotic agents in coronary artery disease.

作者: J A Cairns.;J Hirsh.;H D Lewis.;L Resnekov.;P Théroux.
来源: Chest. 1992年102卷4 Suppl期456S-481S页

2956. Prevention of venous thromboembolism.

作者: G P Clagett.;F A Anderson.;M N Levine.;E W Salzman.;H B Wheeler.
来源: Chest. 1992年102卷4 Suppl期391S-407S页

2957. Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease.

作者: M H Eckman.;H J Levine.;S G Pauker.
来源: Chest. 1992年102卷4 Suppl期538S-549S页

2958. Antithrombotic therapy in peripheral arterial occlusive disease.

作者: G P Clagett.;R A Graor.;E W Salzman.
来源: Chest. 1992年102卷4 Suppl期516S-528S页

2959. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts following percutaneous transluminal coronary angioplasty.

作者: P D Stein.;J E Dalen.;S Goldman.;L Schwartz.;A G Turpie.;P Théroux.
来源: Chest. 1992年102卷4 Suppl期508S-515S页

2960. Coronary thrombolysis.

作者: J A Cairns.;V Fuster.;J W Kennedy.
来源: Chest. 1992年102卷4 Suppl期482S-507S页
共有 3618 条符合本次的查询结果, 用时 3.6493452 秒